Updated Approaches for Treating Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH)

  • Written for primary care, hepatology, and gastroenterology teams

  • Addresses the need to improve awareness of new nomenclature, improved patient-centered communication, and strategies for coordination across multidisciplinary teams through clinician education

  • Includes discussion of recent FDA approvals, clinical trial results, and updated guidelines issued by the American Association for the Study of Liver Diseases (AASLD)

Next
Next

Needs Assessment: Prostate Cancer